Logo
x

Search

Subscribe Now

Syndax Pharmaceuticals

Syndax Pharmaceuticals’ Revuforj (Revumenib) Receives the US FDA’s Approval for R/R Acute Leukemia

Syndax Pharmaceuticals’ Revuforj (Revumenib) Receives the US FDA’s Approval for R/R Acute Leukemia

  • November 15, 2024
Syndax Publishes the Pivotal AUGMENT-101 Study Data of Revumenib for R/R KMT2Ar Acute Leukemia in the Journal of Clinical Oncology

Syndax Publishes the Pivotal AUGMENT-101 Study Data of Revumenib for R/R KMT2Ar Acute Leukemia in the Journal of Clinical Oncology

  • August 13, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.